Regenetech increases cell multiplication capabilites

Regenetech, a USA-based adult stem cell company, says it has significantly augmented its cell multiplication capabilities for CD34+38- peripheral blood progenitor cells, also known as adult stem cells. According to the firm, these new results were achieved through the continued development of cell culture conditions in its proprietary and patented Intrifuge cellXpansion platform.

Developing a significant and reliable technology for adult stem cell growth and multiplication currently represents one of the most significant barriers preventing their more widespread therapeutic use.

Under the new, improved growth conditions, the number of adult stem cells increased 50-200 times the original number, an achievement accomplished in as few as six days. Compared to other serum-free media, the optimized Regenetech formulation yields considerably higher cell numbers than were previously achievable, significantly enhancing the market competitiveness and commercial potential of the cellXpansion technology.